- Home
- TURN vs ADVM Comparison
TURN vs ADVM Comparison
Compare TURN & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- ADVM
- Stock Information
- Founded
- TURN 1981
- ADVM 2006
- Country
- TURN United States
- ADVM United States
- Employees
- TURN N/A
- ADVM N/A
- Industry
- TURN Finance/Investors Services
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TURN Finance
- ADVM Health Care
- Exchange
- TURN Nasdaq
- ADVM Nasdaq
- Market Cap
- TURN 42.5M
- ADVM 49.9M
- IPO Year
- TURN N/A
- ADVM 2014
- Fundamental
- Price
- TURN $4.38
- ADVM $2.29
- Analyst Decision
- TURN
- ADVM Strong Buy
- Analyst Count
- TURN 0
- ADVM 5
- Target Price
- TURN N/A
- ADVM $23.80
- AVG Volume (30 Days)
- TURN 33.4K
- ADVM 114.7K
- Earning Date
- TURN 01-01-0001
- ADVM 08-19-2025
- Dividend Yield
- TURN N/A
- ADVM N/A
- EPS Growth
- TURN N/A
- ADVM N/A
- EPS
- TURN N/A
- ADVM N/A
- Revenue
- TURN $194,813.00
- ADVM $1,000,000.00
- Revenue This Year
- TURN N/A
- ADVM N/A
- Revenue Next Year
- TURN N/A
- ADVM $18.82
- P/E Ratio
- TURN N/A
- ADVM N/A
- Revenue Growth
- TURN 254.25
- ADVM N/A
- 52 Week Low
- TURN $3.12
- ADVM $1.78
- 52 Week High
- TURN $4.47
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- TURN 68.11
- ADVM 40.02
- Support Level
- TURN $4.25
- ADVM $2.39
- Resistance Level
- TURN $4.31
- ADVM $2.57
- Average True Range (ATR)
- TURN 0.10
- ADVM 0.20
- MACD
- TURN 0.01
- ADVM -0.03
- Stochastic Oscillator
- TURN 76.92
- ADVM 3.45
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.